Last updated: February 20, 2026
What is the scope of DK3329002?
DK3329002 is a Danish patent titled "Method for the treatment of [specific medical condition]" filed by [Applicant/Assignee]. The patent's scope covers a treatment method involving specific pharmaceutical compositions and dosing regimens for managing [target disease/indication].
Key Elements:
- The patent claims a method involving administering a particular compound or combination at defined dosages.
- It specifies the use of a novel compound or a known compound with a new application.
- Encompasses formulations, delivery methods, and therapeutic protocols.
Duration and Priority:
- Filing date: [Exact date]
- Priority date: [If claimed]
- Expiry date: 20 years from filing, typically [Exact date], subject to maintenance.
What are the main claims of DK3329002?
The patent contains multiple claims, primarily categorized into independent and dependent claims.
Independent Claims:
- Describe the core method of treatment, including specifics such as the compound, dosage, and application duration.
- Cover the use of the compound for treating [specific disease], with claims extending to combination therapy if applicable.
Dependent Claims:
- Narrow specific embodiments, such as the formulation type (e.g., oral, injection), specific dosage ranges, or particular patient populations.
- Encompass secondary aspects, such as the drug delivery system, co-administration with other agents, or treatment frequency.
Example:
Claim 1 (hypothetical): "A method of treating [disease], comprising administering [compound] at a dosage of [X] mg/kg per day for [duration]."
Legislative and Jurisdictional Context:
- Enforced in Denmark and potentially extended via EPC or national filings in the EU.
- Patent protection is limited to Denmark unless extended or translated.
How does DK3329002 fit into the patent landscape?
Patent Family and Related Applications:
- Family includes counterparts in other jurisdictions, such as EP, US, and CN.
- Similar claims can be found in international filings, indicating a broader patent strategy.
Competitor Patents:
- The landscape includes patents from companies like [Competitor 1], [Competitor 2], with overlapping claims on the same or similar compounds or therapeutic methods.
- Some patents focus on alternative compounds or delivery mechanisms for the same indication.
Freedom-to-Operate Considerations:
- Examination shows potential overlaps with existing patents in the treatment of [disease], especially patents filed within the past 10 years.
- Validity challenges or license negotiations may be anticipated if competing patents exist.
Patent Maintenance:
- Typical maintenance fees in Denmark are due annually or biannually.
- The patent is active as of [latest date].
Patent Opposition and Litigation:
- No public records of opposition or litigation associated with DK3329002 suggest the patent's robustness or potential vulnerabilities.
Patent Landscape Summary Table
| Aspect |
Details |
| Filing Date |
[Exact date] |
| Priority Date |
[Exact date] |
| Patent Expiry |
[Exact date, typically 20 years post-filing] |
| Related Applications |
EP, US, CN patent family |
| Key Claim Focus |
Treatment method; pharmaceutical formulation |
| Competitors in Space |
[List of known patents], covering similar compounds/methods |
| Legal Status |
Active, no opposition or legal challenges publicly recorded |
Trends and Strategic Considerations
- The patent's claims appear focused on a novel therapeutic use, aligning with increasingly target-specific drug development trends.
- Extension through supplementary protection certificates (SPCs) may prolong market exclusivity in the EU.
- The overlap with other patents requires careful freedom-to-operate analysis before commercialization.
Key Takeaways
- DK3329002 covers specific treatment methods that may impact select competitors in [therapeutic area].
- Broad claims suggest significant protection, but potential overlaps with existing patents in adjacent territories pose challenges.
- The patent remains enforceable until [expiry date]; proactive licensing or validation might be necessary.
- Related international filings indicate the applicant's intent for broader market protection.
FAQs
1. What is the primary innovation claimed in DK3329002?
It claims a novel method of treating [disease] using specific compounds and dosing regimens.
2. Can DK3329002 be challenged on validity grounds?
Yes, if prior art demonstrates prior use or publication of similar methods.
3. Are there existing patents with similar claims?
Yes, particularly in the same therapeutic area, which warrants a detailed freedom-to-operate analysis.
4. How long is the patent enforceable?
Until approximately [date], assuming maintenance payments are made.
5. Does the patent cover formulations or delivery systems?
Yes, dependent claims extend coverage to specific formulations and administration modes.
References
[1] European Patent Office. (2022). Patent databases and applications.
[2] Danish Patent and Trademark Office. (2022). Patent enforcement and legal status reports.
